First Horizon National Corporation (NYSE:FHN) is struggling to gain traction with investors, as evidenced by its 4.36 million shares volume. The daily trading volume average remained 3.16 million shares over the course of 3 months. The stock had opened the regular trading at $19.14 and managed a 1.35% price change to reach $19.46 through the close.First Horizon National Corporation (FHN) Analyst Opinion
First Horizon National Corporation has a consensus outperform rating from 19 Wall Street analysts, and the number of shares currently sold short amount to at least 7.35% of shares outstanding. The stock spiked 4.18% last month and is down -2.65 this year. Wall Street is only getting more bullish on the stock, with 12 of analysts who cover FHN having a buy-equivalent rating. Analysts have placed a $22.32 price target on First Horizon National Corporation, suggesting a 14.7% gain from recent close. It’s currently trading about -6.71% below its 52-week high.
First Horizon National Corporation (FHN) surprised the stock market in its last reported earnings when it earned $0.34 a piece versus the consensus-estimated $0.31. Its revenue totaled $440.46 million up 17.37% from the previous quarter.First Horizon National Corporation (NYSE:FHN) Intraday View
This stock (FHN) is ahead of its 52-week low with 22.85%. Its last month’s stock price volatility remained 1.73% which for the week stands at 1.85%. The share price has moved forward from its 20 days moving average, trading at a distance of 4.34% and stays 2.43% away from its 50 days moving average. Over the last five days, shares have managed 3.57% gains and now is up 2.88% since hitting its 200-day moving average of $19.34. First Horizon National Corporation (FHN) has made its way to a 12-month gain of 9.63%.
Turning to Inovio Pharmaceuticals, Inc. (NASDAQ:INO), its shares were trading at $5.1 a gain of $0.1, on the trading floor. The stock, after opening at $5, touched a high of $5.15 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.7. Inovio Pharmaceuticals, Inc. has 2 buy ratings, 0 holds and 0 sells even after the stock tumbled -48.28% from its high of $9.86 to a $489.96 million market value through last close.
The company’s consensus rating on Reuter’s scale slipped from 1.67 to 1.6 during a month. Analysts set a 12-month price target of $11.67 a share. The target implies a 128.82% spike from where the shares are currently trading. Also, the current price highlights a discount of 154.9% to analysts’ high consensus price target.Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Intraday Trading
The counter witnessed a trading volume of 1.61 million shares versus an average volume of 1.02 million shares during last trading session. Its last month’s stock price volatility remained 5.08% which for the week approaches 4.19%. The lowest price the stock reached in the last trading day was $4.98 and compares with the $3.76 52-week low. The stock recovered 35.64% since its low point and has performed 23.49% year-to-date.